Allelic imbalance and biochemical outcome after radical prostatectomy

Abstract

Objective: To compare the incidence of allelic imbalance (AI) in men with rapid disease progression with those who remained disease free after radical prostatectomy, with the aim of identifying genetic markers to predict prognosis and guide further treatment. Patients and methods: Tumour and normal DNA were extracted from two matched groups of 31 men with extracapsular node-negative (pT3N0) prostate cancer who had undergone radical prostatectomy. One group comprised men who developed biochemical recurrence within 2 years of surgery and one group were prostate-specific antigen (PSA) free for at least 3 years. Men were matched for Gleason grade, preoperative PSA and pathological stage. Analysis was performed by genotyping. Results: Allelic imbalance was analysed using 30 markers, and was seen in at least one marker in 57 (92%) of the cases. Deletion at marker D10S211 (10p12.1) was significantly more common in the relapse group than the non-relapse group (35 vs 5%, P ¼ 0.03). Conclusions: This study demonstrates significant association between AI on chromosome 10 and biochemical progression after radical prostatectomy.

DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer

“…BCR/clinical relapse of PCa is the most common characteristic of clinical outcomes that have been investigated for association with CNAs. 7 34 66 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 The most frequently investigated candidate genes include PTEN on 10q23.31 and MYC on 8q24.21 ( Table 1 ). Significant associations between PTEN loss and PCa recurrence have been reported in multiple cohorts.…”